Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company based in Bedminster, NJ, specializing in the development of breakthrough small molecule therapeutics for genetically-defined cancers and autoimmune disorders. With a focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms, Jubilant Therapeutics aims to create first-in-class programs with fast-track and breakthrough potential. Leveraging their world-class research capabilities and in-house development expertise, the company is dedicated to advancing promising assets from discovery to clinical proof of concept and ultimately commercialization through strategic collaborations.
Jubilant Therapeutics' portfolio consists of potent and selective small molecule modulators, with a goal to address the unmet medical needs of patients with oncology and auto-immune diseases. By leveraging innovation and precision medicine, the company aims to provide safety and therapeutic advantages in the field of cancer and immunology. With a commitment to creative partnerships and a strong emphasis on research and development, Jubilant Therapeutics is at the forefront of advancing precision therapeutics to improve patient outcomes.
Generated from the website